In the second session of Nanopharm’s fireside series in partnership with FLUIDDA, industry experts Drs. Will Ganley and Eleanor Canipa from Nanopharm and Dr. Jan De Backer from Fluidda provide their thoughts on what the updated PSGs and alternative bioequivalence tell us about the FDA’s position on inhaled generics.